Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00365768 · BASELINE

Baseline characteristics

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors · Source last updated 2016-09-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      24
    2. group Id
      BG001
      value
      25
    3. group Id
      BG002
      value
      49
    units
    Participants
groups
  1. description
    Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21. Glutamine: Administered orally twice daily for 21 days
    id
    BG000
    title
    Arm I: Glutamine
  2. description
    Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21. Placebo: Administered orally twice daily for 21 days
    id
    BG001
    title
    Arm II: Placebo
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          5
          upper Limit
          19
          value
          11
        2. group Id
          BG001
          lower Limit
          4
          upper Limit
          17
          value
          10
        3. group Id
          BG002
          lower Limit
          4
          upper Limit
          19
          value
          11
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          14
        2. group Id
          BG001
          value
          12
        3. group Id
          BG002
          value
          26
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          10
        2. group Id
          BG001
          value
          13
        3. group Id
          BG002
          value
          23
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          24
        2. group Id
          BG001
          value
          25
        3. group Id
          BG002
          value
          49
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
population Description
Fifty-six patients were enrolled and 49 were evaluable.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      24
    2. group Id
      BG001
      value
      25
    3. group Id
      BG002
      value
      49
    units
    Participants
groups
  1. description
    Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21. Glutamine: Administered orally twice daily for 21 days
    id
    BG000
    title
    Arm I: Glutamine
  2. description
    Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21. Placebo: Administered orally twice daily for 21 days
    id
    BG001
    title
    Arm II: Placebo
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          5
          upper Limit
          19
          value
          11
        2. group Id
          BG001
          lower Limit
          4
          upper Limit
          17
          value
          10
        3. group Id
          BG002
          lower Limit
          4
          upper Limit
          19
          value
          11
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          14
        2. group Id
          BG001
          value
          12
        3. group Id
          BG002
          value
          26
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          10
        2. group Id
          BG001
          value
          13
        3. group Id
          BG002
          value
          23
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          24
        2. group Id
          BG001
          value
          25
        3. group Id
          BG002
          value
          49
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
population Description
Fifty-six patients were enrolled and 49 were evaluable.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice